Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.
Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.
Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.
All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the grant of non-qualified stock options to purchase a total of 114,600 shares to ten new employees under its 2019 Inducement Equity Incentive Plan. The options, priced at $13.34 per share, align with Nasdaq Listing Rule 5635(c)(4), serving as inducements for employment. The vesting period spans four years, with 25% vesting after the first year. Spero is focused on developing treatments for multi-drug-resistant infections and rare diseases, with key candidates including tebipenem HBr and SPR720.
Spero Therapeutics (Nasdaq: SPRO) announced a conference call scheduled for August 5, 2021, at 4:30 p.m. ET to discuss its Q2 2021 financial results and provide an update on its business and pipeline. The company is focused on developing treatments for multi-drug resistant bacterial infections and rare diseases. Its lead product, tebibenem HBr, is in a Phase 3 trial for complicated urinary tract infections. Archived webcasts will be available for 30 days post-call on their website.
Spero Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: SPRO), announced that Dr. Ankit Mahadevia will present at the virtual Ladenburg Thalmann Healthcare Conference on July 13, 2021, at 10:30 AM ET. The presentation will cover advancements in treatments for multi-drug resistant infections and rare diseases, including the lead product candidate, tebipenem HBr, aimed at urinary tract infections. Investors can register for the event via a provided link, and a replay will be available on Spero's website after the presentation.
Everest Medicines announced a licensing agreement between its partner Spero Therapeutics and Pfizer for SPR206, a new treatment for multi-drug resistant Gram-negative infections. Under this deal, Spero will receive up to $80 million in milestone payments and royalties on sales, alongside a $40 million equity investment from Pfizer. This partnership enhances the clinical development of SPR206 while maintaining Everest's exclusive rights in Greater China, South Korea, and certain Southeast Asian countries.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced the grant of non-qualified stock options for 85,650 shares to nine new employees on June 30, 2021. This grant, part of the 2019 Inducement Equity Incentive Plan, aims to incentivize new hires as per Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $13.96 per share and will vest over four years, with 25% vesting after one year. Spero focuses on treatments for multi-drug resistant infections and rare diseases, with lead product candidate tebipenem HBr showing promising clinical trial results.
Spero Therapeutics has partnered with Pfizer to develop and commercialize SPR206, a treatment for multi-drug resistant bacterial infections, in territories outside the U.S. and Asia. Pfizer's $40 million equity investment in Spero will support the clinical development of SPR206 and SPR720, along with preparations for the NDA filing of tebipenem HBr. Spero stands to gain up to $80 million in milestone payments and royalties from SPR206 sales. The funding extends Spero's cash runway into late 2022, emphasizing the need for effective treatments for antimicrobial resistance.
Spero Therapeutics (Nasdaq: SPRO) has initiated two Phase 1 clinical trials for SPR206, a next-generation polymyxin aimed at treating multi-drug resistant (MDR) Gram-negative infections. The trials will assess SPR206's pharmacokinetics in pulmonary and renal impairments, critical for hospital-acquired pneumonia and ventilator-associated pneumonia treatment. Results are expected by early 2022, following previous Phase 1 data indicating a favorable safety profile and no nephrotoxicity. The trials are supported by the Department of Defense, marking a significant step in combating MDR infections.
Spero Therapeutics, Inc. (Nasdaq: SPRO) announced on May 28, 2021, the granting of 36,000 non-qualified stock options to seven new employees under the 2019 Inducement Equity Incentive Plan. The exercise price for these options is $14.50 per share, matching Spero's closing stock price on the grant date. Options will vest over four years, with 25% vesting after one year and the remainder monthly thereafter. This plan aims to attract and retain talent critical for developing treatments for multi-drug resistant infections and rare diseases.
Spero Therapeutics (Nasdaq: SPRO) announced funding of $2.09 million from the National Institute of Allergy and Infectious Diseases (NIAID) for the clinical development of SPR206, a next-generation polymyxin product targeting multi-drug resistant Gram-negative infections. The funding could total up to $21.3 million over five years, facilitating studies required for FDA approval, including pharmacokinetics and a Phase 2 proof-of-concept trial. The award underscores the program's external validation and highlights SPR206’s potential to address serious drug-resistant infections.
On May 13, 2021, Spero Therapeutics (Nasdaq: SPRO) announced that CEO Ankit Mahadevia will participate in a virtual fireside chat at the Berenberg Conference USA, scheduled for May 18, 2021, at 2:00 PM ET. The event will discuss Spero's focus on combating multi-drug resistant bacterial infections and rare diseases. Investors can access the chat through a provided webcast link. Spero's key product, tebipenem HBr, is being developed as the first oral carbapenem antibiotic for complicated urinary tract infections. More about Spero can be found on their website.
